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In order for a phytotherapeutic drug be approved and sold in Brazil, it must be registered with the 
National Sanitary Surveillance Agency (ANVISA), where the quality, safety and efficacy of the product 
are carefully appraised. In addition, the drug must also meet a number of criteria one of which is the 
adequacy of the package inserts. Therefore, the aim of this study was to appraise the package inserts of 
all phytotherapeutic drugs produced using a standardized extract of Pelargonium sidoides, which were 
registered and available from Brazilian pharmacies. This checking was to ascertain whether these inserts 
fulfilled the requirements stipulated by RDC 140/03. The information required under RDC 140/03 was 
appraised through a previously devised standard form. Evaluation of the package inserts revealed that 
neither of the two brands fully met the requirements of the legislation. Manufacturer ‘A’ met only 37.0% 
of the requirements satisfactorily, while 16.0% of the information was considered unsatisfactory and 
47.0% of the information was absent. Regarding manufacturer ‘B’, 64.2% of the analyzed requirements 
were considered satisfactory, while 16.0% were considered unsatisfactory and 19.8% of the information 
was absent. A package insert should contain information about medicine for consumers, pharmacists and 
doctors. However, the results obtained in this study showed that the information presented in the package 
insert of both medicines was unsatisfactory, and in many cases, violates the legislation.
Uniterms: Medicines/formulation of package inserts. Phytotherapeutic drugs. Package inserts/evaluation. 
Pelargonium sidoides.
Para que um medicamento fitoterápico seja comercializado no Brasil, este deve ser registrado junto à 
ANVISA, onde são avaliados todos os aspectos referentes à qualidade, segurança e eficácia do produto, 
além de verificar se estes atendem alguns requisitos, sendo um deles a adequação da bula. Por esta razão, 
neste estudo foram avaliadas as bulas de todos os fitoterápicos elaborados à base do extrato padronizado de 
Pelargonium sidoides, registrados e disponíveis no mercado brasileiro, com o intuito de verificar se estas 
atendem aos requisitos exigidos pela RDC 140/03. No presente trabalho, as informações exigidas pela 
RDC 140/03 foram avaliadas através de um formulário padrão previamente elaborado. Após avaliação das 
bulas pode ser verificado que nenhuma das duas marcas atendia por completo as exigências da legislação, 
sendo que o fabricante “A” atendeu apenas 37,0% dos requisitos exigidos de forma satisfatória, enquanto 
16,0% das informações foram consideradas insatisfatórias e em 47,0% as informações estavam ausentes. 
Com relação ao fabricante “B”, 64,2% dos itens analisados foram considerados satisfatórios, enquanto 
16,0% foram considerados insatisfatório e em 19,8% as informações estavam ausentes. A bula deveria 
conter informações sobre o medicamento para consumidores, farmacêuticos e médicos, no entanto, os 
resultados obtidos neste estudo mostram que as informações apresentadas nas bulas foram insatisfatórias, 
e em muitos casos, violavam a legislação vigente.
Unitermos: Medicamentos/formulação de bulários. Fitoterápicos. Bulas/avaliação. Pelargonium sidoides.
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INTRODUCTION
Initial Considerations
Up until the beginning of the twentieth century, 
plants and vegetal extracts were the main sources of the-
rapeutic resources. With the impact caused by the advent 
of important pharmaceutical synthetic elements, natural 
medicines started to become relegated as a second option. 
Nevertheless, in the past few years, the resumption of 
phytotherapeutic medicine use has increased markedly 
(Bello et al., 2002). The population on the other hand, 
has little information concerning the use of this kind of 
medicine and the majority thinks that phytotherapeutic 
medicines offer no risks to their health and have no side 
effects. These beliefs can lead to their irrational use and 
self-medication (Amaral et al., 2007).
About the medicine register
Brazilian legislation has steadily been regulating the 
register of phytotherapeutic medicines in Brazil, initially 
with SVS decree number 6 of January 31st, 1995, upda-
ted in 2000 through resolution RDC number 17, by the 
National Sanitary Surveillance Agency (ANVISA) and 
more recently with the enactment of RDC number 48 of 
2004 (Virgílio, Marques, 2004). According to Carvalho 
et al. (2007), for a phytotherapeutic medicine to be com-
mercialized in Brazil it must be registered by ANVISA. 
This register represents the first intervention concerning 
product quality, safety and efficacy. 
For the industry to achieve the register of the medi-
cine it must petition ANVISA, also known as a procedure, 
with a technical dossier containing information about the 
product concerning production, quality control, safety and 
efficacy assays, legally required company data, besides 
medicine labeling and package insert data (Carvalho et 
al., 2007).
In Brazil, the most important source of information 
for medicine users is the package inserts (Silva et al., 
2000; Farias et al., 1985). In light of this, and assuming 
the medicine package inserts should effectively guide both 
patients and health professionals regarding the rational use 
of the medicine, resolution RDC number 140/03 was im-
plemented, establishing rules for medicine package inserts 
for the benefit of both patients and health professionals. 
In spite of the compulsory nature of the package 
inserts in the medicine package, they provide very little 
information for patients and health professionals. This is 
the case because of the lack of adaptation of the package 
inserts to meet the current legislation. 
Pelargonium sidoides
The Perlagonium sidoides DC is a plant belonging 
to the family of Geraniaceae, which is found in the Afri-
can continent at a height of 2.300 meters, mainly in South 
Africa and is popularly called umckaloabo. It is characte-
rized for presenting massive dark brown roots, big round 
tipped leaves, an inflorescence that ranges from reddened 
to dark purple, with petals that vary in color. The leaves 
and particularly the roots are the most commonly used 
parts medicinally (Alonso, 2004; Bladt, Wagner, 2007).
Chemical composition
P. sidoides roots present mainly condensed taninns 
in their particular metabolism, highlighting the oligome-
ric proantocianidines formed by at least eight units of 
flavan-3-ol like monomers (afzelequine, catequine and 
galocatequine), and the coumarins escopoletine, fraxidin, 
isofraxedin, arteline, umckalin and its 7-O-methilether 
(5,6,7-trimethoxycoumarin) (Alonso, 2004; Kaiser, Ko-
lodziej, 1995; Bladt, Wagner, 2007; Kolodziej, 2007b). 
It is also possible to find flavonoids (quercetin), terpenes 
(mono and sesquiterpens), phenylpropanoids, and anacar-
dic acid (Alonso, 2004; Bladt, Wagner, 2007).
Pharmacological activities
Several authors (Alonso, 2004; Mativandlela et al., 
2006; Conrad et al., 2007; Matthys, Heger, 2007b; Kolo-
dziej, Kiderlen, 2007a), report that the roots of P. sidoides 
have antimicrobial activity, inhibiting Gram-positive ger-
ms (Staphylococcus aureus, Streptococcus pneumoniae, S. 
beta-hemolitico 1451), Gram-negative germs (Escherichia 
coli, Klebsiella pneumoniae, Proteus mirabilis), virus 
(Haemophilus influenzae, Moraxella catarrhalis), and 
fungus (Aspergillus niger, Fusarium oxysporum, Rhizopus 
stolonifer). Among the components that make this activity 
possible are the coumarins (Alonso, 2004).
The P. sidoides also has, according to traditional use, 
activity for the treatment of tuberculosis (Kolodziej et al., 
2003). Mantivandlela et al. (2006) reported antimycobac-
terial activity of the P. sidoides roots, in vitro, against M. 
tuberculosis.
Several studies, both in vitro and in vivo, as well as 
clinical assays have been performed with a standardized 
extract called EPs 7630, commercialized by a German 
company. Kolodziej and Kiderlen (2007a) verified that 
EPs 7630 has immunomodulating activity. The immunos-
timulating activity occurs due to the presence of couma-
rins and other polifenolic compounds which promote the 
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formation of cytokines that intervene defending against 
anaerobic microorganism infections (Alonso, 2004). Ac-
cording to Neugebauer et al. (2005), EPs 7630 present an 
increase in the frequency of the beating movement of the 
nasal epithelium. This beating movement is an important 
mechanism of physical defense against infections. In the 
in vitro model of fibroblasts infected with the virus of 
brain-miocarditis, the extract of P. sidoides was shown to 
produce alpha and beta interferons, which have recognized 
antiviral effect, where the umckalin and the gaelic acid 
are the main components responsible for these effects 
(Marcucci et al., 1992 apud Alonso, 2004 ). The EPs 7630 
extract also demonstrates action in relieving flu symptoms 
(Noldner, Schotz, 2007).
A study performed using extracts of roots of P. si-
doides, involving 641 patients with infections in the oro-
pharynx (tonsil infection, rhinopharyngitis) and breathing 
(bronchitis, sinusitis), demonstrated that 85% of the pa-
tients experienced significant clinical improvement after a 
fourteen-day course of treatment (Heil, Reitermann, 1994 
apud Alonso, 2004). Several clinical studies (Chuchalin 
et al., 2005; Matthys et al., 2003; Matthys et al., 2007a; 
Matthys, Hereg, 2007b) have also proven the efficacy of 
Eps 7630 for treating bronchitis.
Cumarinic derivates are among the main com-
ponents of P. sidoides. Given this, and considering the 
possibility of this plant having anticlotting activity, Koch, 
Biber (2007) investigated the parameters of blood clotting 
in mice, after administration of the substance, comparing it 
to warfarin. After the oral administration of Eps 7630 for 
two weeks, no effect was observed, in contrast to warfarin, 
which over the same period resulted in significant changes 
in the clotting factor.
Adverse effects
No adverse effects have been reported in patients 
older than 12 years old, noting that the extract of P. si-
doides is well tolerated in therapeutic doses (Tsyrkunov, 
1989; Kolodziej et al., 1997 apud Alonso, 2004; Correia 
et al., 1984 apud Alonso, 2004; Anderson et al., 1992; 
Edenharder et al., 1995 apud Alonso, 2004; Heil, Rei-
termann, 1994 apud Alonso, 2004; Matthys et al., 2003; 
Schotz et al., 2007).
A study performed with extracts of roots of P. si-
doides in 259 children aged up to12 years old that had 
acute bronchitis events, showed that it had good tolerance. 
However, 6 patients (2.3%) showed some adverse effects 
such as: exantema, light dyspnea, intestine spasms, lack 
of appetite, vomiting and restlessness. After suspending 
use of the medicine, patients’ clinical pictures returned to 
normal (Dome, Schuster, 1996 apud Alonso, 2004).
Contraindication
Due to the lack of data indicating the safety of P. 
sidoides use during pregnancy, the use of the product must 
be avoided during gestation and breast-feeding (Alonso, 
2004).
MATERIALS AND METHODS
Analysis of Package Inserts
The study was developed initially through a vast 
bibliographic revision, centering its source of research on 
scientific papers, books, laws, decrees, and resolutions, 
for substantiation and formation of a theoretical basis, 
followed by the devising of a standard form reflecting reso-
lution RDC number 140/03 (Brasil, 2003a), transforming 
its articles into items on a checklist (Table I). 
The purpose of the form was to confirm the presen-
ce of compulsory statement, indications for use, specific 
technical information and legally required content. To this 
end, the previously devised standard form was divided 
into six parts: the 1st part evaluates the size of the lettering; 
the 2nd part evaluates the identification of the medicine; 
the 3rd part, information to patients; the 4th part, technical 
information for health professionals; the 5th part, compul-
sory statement, and the 6th part, legally required content. 
Each aspect checked was classified into one of three pos-
sible categories: (S) Satisfactory - when the information 
conforms to the legislation in a complete or satisfactory 
way; (U) Unsatisfactory - when the information fails to 
fully conform to the legislation; (A) Absent - when no 
information is provided. All the items on the form were 
considered indispensable and, therefore, the weight for 
the evaluation fulfilled only one criterion (weight 1). All 
the items for the medicine package inserts were evaluated 
by three competent pharmaceutical professionals and the 
same result was presented as a whole for the interpretation 
of the forms.
To evaluate if the package insert information was 
rendered in accessible language for the patients and in 
accordance with the International Classification of Dise-
ases (ICD), pursuant to RDC 140/03, both the Brazilian 
Center for Disease Classification (Centro Brasileiro de 
Classificação de Doenças, 2007) and the World Health 
Organization International Statistical Classification of 
Diseases (WHO, 1998) were consulted. The accessibility 
of language to patients was also subjectively evaluated in 
the authors’ interpretation. 
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Acquisition of sample
The sample was formed by the package inserts of 
phytotherapeutic medicines derived from standardized 
extract of roots of Pelargonium sidoide commercialized 
in Brazil. Two such products were found to be registered 
on ANVISA’s official site. The samples were acquired 
from drugstores in the municipalities of Campos dos 
Goytacazes-Rio de Janeiro State, between September and 
October / 2007, with the manufacturer “A” product bearing 
batch number 70628 while the manufacturer “B” product 
had a batch number of 702720. 
RESULTS AND DISCUSSION
These products containing standardized extract 
of roots of P. sidoides found registered by ANVISA up 
to the year of 2007 were both produced by far-reaching 
laboratories which have strong advertising and marketing 
appeal in the national milieu, achieving notable success 
in pharmaceutical sales according to data available on the 
official sites of the respective companies. Manufacturer 
“A” is an Anonymous Society (Inc.), and therefore has to 
release its financial statements and results in the Official 
Gazette of the Federal Executive (Diário Oficial da União) 
or a prevalent newspaper with a broad coverage, every 
end of business year. Manufacturer “B” was a Limited 
Society (Ltd.) and made available on its site information 
concerning its annual revenues, which in 2007 was higher 
than R$ 500.000.000,00 (five hundred million reais). 
Concerning sanitary regulations in Brazil, the company 
may be rated as far-reaching (Group I) if it has a turnover 
which is higher than fifty million reais (ANVISA, 2008).
Analysis of Package Inserts
1st Part: Size of the lettering 
Both medicine package inserts conformed to the 
legislation concerning the compulsory characteristic of 
the presentation of the lettering at a minimum size of 1.5 
mm (Table I), allowing reading without difficulties, es-
pecially for elderly patients who often have more trouble 
reading.
2nd Part: Identification of the medicine
As evidenced in Table I, manufacturer “A” confor-
med to the legislation satisfactorily on 77.8% of the items 
and no items were considered unsatisfactory, although 
22.2% of these were found to be absent. Manufacturer “B” 
conformed to the legislation on 77.8% of requirements 
satisfactorily and on 22.2% unsatisfactorily (Figure 1).
The commercialized presentations were properly 
described by both manufacturers, including the pharma-
ceutical forms, commercial name or brand of the medicine, 
official botanic nomenclature, administration route, liquid 
volume and the part of the plant used. 
Concerning the qualitative and quantitative des-
cription of the active ingredients, “A” described this 
incompletely in stating that the product contained 825 mg 
of liquid extract of the root of P. sidoides and a sufficient 
amount for 1ml of the vehicle, but omitted the informa-
tion on which vehicle was being referred to. Manufac-
turer “B” presented glycerol as its vehicle and a wide 
spectrum of variation of levels of a non-specified class 
of active ingredient (0.08% to 0.32% of total phenols) 
as markers. However, the medicines should clearly state 
the active ingredients, such as coumarins and taninns 
(Alonso, 2004; Kaiser, Kolodziej, 1995; Kolodziej, 
2007b), and therefore the information presented by both 
manufactures was considered lacking. 
In addition, the two manufacturers cited here also 
omitted other components in the formula, such as coloring, 
flavoring, edulcoloring, stabilizers among other common 
items used in the manufacture of oral solutions for both 
pediatrics and adult use (Ansel et al., 2000). 
It is important to highlight that, according to Resolu-
tion RDC 137/2003 (Brasil, 2003b), there are substances 
for which it is necessary to include compulsory sentences 
in the package inserts where packages must highlight the 
danger of their use by special groups (i.e. diabetics, ce-
liacs, phenylketonurics), or provide warnings for patients 
who have allergies to them (i.e. tartazine yellow). As the 
excipients which have been used were not described in 
the package inserts, in the manner stipulated by RDC 
140/2003, these could not be evaluated (Brasil, 2003a).
Furthermore, the absence and total non-specification 
FIGURE 1 – Evaluation of the item “identification of the 
medicine” for the package inserts by manufacturers “A” and 
“B” of P. sidoides-based phytotherapeutics.
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of excipients infringes not only sanitation regulations, but 
also the Consumer Defense Code (Brasil, 1990).
3rd Part: Information to patients
The required items that constitute correct informa-
tion for the patient are presented in Table I, which shows 
that manufacturer “A” conformed to the legislation satis-
factorily on 41.7% of the items, unsatisfactorily on 25% 
whereas for 33.3% of items the information was absent. 
Manufacturer “B” conformed to the legislation in appro-
ximately 58.4% of items satisfactorily, in 20.8% unsatis-
factorily while 20.8% of items were absent (Figure 2).
With regard to the “information to patients”, the 
package inserts of both medicines satisfactorily presen-
ted physical aspects, procedures for use of the medicine, 
intervals of administration, dosage, in accordance with 
the pharmaceutical form, administration route, warnings, 
contraindication and precautions. 
However, with regard to the “medicine action”, ma-
nufacturer “A” only reported the pharmacological action 
of the medicine, not informing the estimated average time 
of action, in contrast to manufacturer “B” that reported 
pharmacological action, estimated average time for the 
action of the medicine, and the estimated time for full 
patient treatment.
Concerning the “medicine storage”, manufacturer 
“A” omitted this item, not giving any information about 
the correct storage procedure, before or after opening. 
Regarding manufacturer “B”, the information was also 
incomplete, in that it only informed the expiry date after 
opening, while omitting the precautions patients should 
take in storing the medicine before and after opening. 
Manufacturer “B” also reported that the medicine was 
made up by vegetal extracts, and for this reason may 
present a tendency for darkening, small variations in 
both color and taste, without altering the effectiveness 
of the product. However, these problems may be caused 
by the inappropriate storage of the product (Brasil, 2001; 
Brasil, 2006).
The inappropriate storage of the medicine may cause 
the growth of fungus and bacteria, or may provoke altera-
tions in the consistency, taste, odor and color, besides the 
acceleration of chemical reactions which lead to decom-
position of the product and alterations in its effectiveness 
(Brasil, 2001; Brasil, 2006).
In the part indicating use of the medicine, both ma-
nufacturers “A” and “B” proved satisfactory in reporting 
this information.
Concerning the language approach, manufacturer 
“A” presented satisfactory language, although it did not 
fully meet ICD requirements, presenting terminologies 
that are not easy for patients to understand, such as: “im-
munomodulating action”, “immunologic system restora-
tion”, “rhinopharyngitis”. The insert for Manufacturer “B” 
medicine not only presented a clear text, but also reported 
the main symptoms for each illness. However, this also 
failed to fully conform to ICD requirements by using ter-
minology such as: “tonsilar angina”, “rhinopharyngitis”.
None of the manufacturers fully presented the orga-
noleptic characteristics of the medicine. In both package 
inserts, only the color was described while omitting the 
other characteristics such as the consistency and odor, 
making it impossible for patients to check if the medicine 
was within the standards for consumption or was “rotten”. 
Manufacturer “A” omitted information concerning 
the required conduct in the event of forgetting to take the 
medicine. The lack of this information may lead the pa-
tient to taking an overdose, due to the false notion that the 
skipped doses should all be taken at once. Manufacturer 
“B” informed the correct procedure for patients, besides 
explaining that the patient should not take a double dose. 
Manufacturer “B” also clearly stated the duration of 
the treatment, and presented supplementary information 
on the maximum treatment period, besides recommen-
dations against stopping the treatment immediately after 
symptoms disappear, explaining that the treatment should 
be continued for some days to avoid recurrence of the ill-
ness. Manufacturer “A” presented no information about 
the duration of the treatment, although it presented instruc-
tions on continuing the treatment for some days after the 
resolution of symptoms in order to prevent recurrence. The 
lack of complete information on the package inserts could 
lead to patients using the medicine continually. 
Concerning the dosage, according to the pharma-
ceutical form and its respective instructions for use, both 
FIGURE 2 - Evaluation of item “Information to patients” in 
package inserts by manufacturers “A” and “B” for P. sidoide-
based phytotherapeutics.
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manufacturers described them satisfactorily. Manufacturer 
“B” also instructed the patient about the recommended 
amount and dosage in case of subsequent treatment (chro-
nic evolution of the illness or frequent recurrence), thus 
not limiting the information only to that required by the 
legislation. However, neither of the manufacturers pre-
sented the dosage for special illnesses or situations. The 
adverse reactions were reported by both manufacturers, 
although neither of them informed the adverse reactions 
including migraine, light dyspnea, lack of appetite and 
restlessness, which may occur in children aged up to 12 
years old (Dome, Schuster, 1996 apud Alonso, 2004).
In the medicinal part, both manufacturers “A” and 
“B” described feeding and laboratory test interactions 
only with coumarin derivates owing to their increase in 
the anticlotting action of the medicine. As P. sidoides 
contains large amounts of coumarins in its composition, 
the administration of this phytotherapeutic in combination 
with others rich in coumarin (i.e. meliloto) and/or anticlot-
ting (warfarin) may lead to an increase in the inhibiting 
effect of clotting.
A more detailed study of the possible interactions 
of P. sidoides with other medicines is recommended as 
well as on feeding interactions and laboratory tests (Koch, 
Biber, 2007).
Regarding restrictions for groups at risk, manufac-
turer “A” reported no restrictions concerning the use of 
the medicine, which may lead the patient to understan-
ding that this medicine may be safely used by anybody, 
including new-borns, children, adults, elderly people, sick 
individuals and so on. On the other hand, manufacturer 
“B” advised against the use of the medicine by pregnant 
women or those who are breast feeding, without doctors’ 
advice, or in infants younger than one year old, due to the 
lack of clinical trials. 
Both manufacturers omitted the statements on the 
risks of use by non-recommended administration routes 
required by law.
Neither of the manufacturers satisfactorily described 
the measures to be taken by patients in the event of over-
dose. Manufacturer “A” reported an absence of studies 
on overdose, and that in the event of overdose the patient 
should seek medical attention immediately. In contrast, 
manufacturer “B” reported that this was a phytotherapeutic 
medicine which is well tolerated, and in case of accidental 
ingestion of doses much higher than those recommended, 
the patient should take the usual measurements for con-
trolling vital functions. It is important to highlight that 
most of the population do not know what “control of vital 
functions” stands for, and therefore neither the procedure, 
nor the language is easily accessible to patients.
4th Part: Technical information for health professionals
The items required according to RDC 140/03 for 
the “technical information for health professional” are 
presented in Table I, which shows that manufacturer “A” 
conformed to the legislation satisfactorily on only 3.4% 
of the items, and unsatisfactorily for 10.3% while 86.3% 
of the items were absent. Manufacturer “B” met the requi-
rements of the legislation satisfactorily in 44.8% of items, 
20.7% were regarded as unsatisfactory and 34.5% of the 
items were absent (Figure 3).
In the part on technical information, manufacturer 
“A” was totally lacking informing this in an unsatisfac-
tory way providing only the care with storage, pharma-
cological characteristics and indications of the medicine. 
The further information required by the legislation was 
not included.
On the other hand, manufacturer “B” satisfactorily 
informed the warning concerning the use of the medicine 
by children and adults, administration route, besides the 
advice against taking the medicine without a doctor or 
surgeon dentist’s recommendation in case of pregnancy 
or breast feeding. Both manufacturers “A” and “B” unsa-
tisfactorily described the steps for storing the medicine, 
since it was only reported that the medicine must be kept 
at ambient temperature, ranging from 15 ºC to 30 ºC, not 
specifying that the medicine must not be stored in damp 
places or those exposed to sun. Both manufacturers also 
omitted the product care concerning the keeping of the 
medicine after opening. Manufacturer “B” however, pre-
sented the expiry date after the flask was opened.
Improper medicine storage may cause the growth 
of fungi and bacteria, and may lead to alterations in its 
consistency, taste, odor and color, besides alterations and 
FIGURE 3 – Evaluation of the item “Technical Information 
for Health Professionals” for the package inserts of 
both manufacturers “A” and “B” of P. sidoides-based 
phytotherapeutics
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deterioration of the medicine, accelerating chemical reac-
tions causing rotting of the products and alteration in their 
effectiveness (Brasil, 2001; Brasil, 2006). 
Manufacturer “B” presented incomplete information 
regarding its storage and reported on the package inserts 
that the medicine is made up of vegetal extracts and that 
for this reason, it may present darkening, small variations 
of color and taste, which do not alter the efficacy of the 
product. However, as was reported above, the inappro-
priate storage of the product may also cause alteration in 
taste, color and efficacy.
Regarding pharmacological characteristics, manu-
facturer “A” informed them in an unsatisfactory way, in 
that it presented the medicine indications while not infor-
ming either its pharmacodynamics or pharmacokinetic 
action, and justifying it with the statement: “no pharma-
cokinetic studies are available”. The same occurred with 
manufacturer “B”, in that it also presented only the indi-
cations of the medicine, omitting its pharmacodynamics 
and pharmacokinetic action, and justifying this with the 
statement “the pharmacokinetic data about the individual 
substances present in the vegetal extracts of P. sidoides 
(EPs 7630) are not yet available”.
Manufacturer “A” informed the indications of the 
medicine in a confusing manner, whereas manufacturer 
“B”, besides informing the indications in a very clear 
manner, also described the main symptoms of each illness 
and the mechanism of action of the indications of the 
medicine, in the part on pharmacological characteristics, 
facilitating understanding for health professionals. Regar-
ding medicinal and feeding interactions and laboratory 
tests, manufacturer “A” reported no information about 
the possible interactions. In contrast, manufacturer “B” 
reported interaction with coumarin derivates, because 
it may have anti clotting effect (Koch, Biber, 2007). As 
the P. sidoides contains large amounts of coumarins in its 
composition, the administration of this phytotherapeutic 
in combination with others rich in coumarin (i.e. Melilotus 
officinalis) and/or anti clotting (warfarin) agents may lead 
to an increase in clotting inhibiting effects.
Concerning the language used, manufacturer “A” 
presented information using simple and easy to unders-
tand language. Manufacturer “B”, besides presenting 
very understandable text, reported the main symptoms 
for each illness. 
Manufacturer “B” reported by means of statements 
and illustrations, the correct handling of the medicine, 
besides the correct way of preparing and applying the 
medicine, thereby easing understanding. Manufacturer 
“A” omitted this information.
Regarding the dose and duration of the treatment, 
manufacturer “B”, besides describing this in a satisfactory 
way, advised which dose was recommended in cases of 
subsequent treatments, thereby not limiting information to 
that stipulated by the legislation. However, information on 
the maximum daily dose was not given. Manufacturer “A” 
did not report any information about the dose, duration of 
the treatment or maximum daily dose. 
According to the current regulation, it is compulsory 
to express quantitatively the active components present 
in the standardized extracts per dose, data which was not 
found in either of the analyzed package inserts.
Although both of the inserts indicated proportions 
regarding the amount of liquid extract, they did not cite the 
percentage or amount of their constituent active chemicals 
(coumarins and taninns).
Manufacturer “A” did not report any adverse re-
actions of the medicine, omitting therefore the several 
reactions that the medicine may cause.
Manufacturer “B” on the other hand reported the due 
adverse reaction, but did not inform some reactions such 
as: migraine, light dyspnea, lack of appetite and restless-
ness, which may manifest in children aged up to 12 years 
old (Dome, Schuster, 1996 apud Alonso, 2004).
Concerning the results on efficacy, manufacturer 
“B” reported the results incompletely, with the due sources 
incorrectly citing the author, title of the article, journal 
page and date of publication. Manufacturer “A” omitted 
all the data, raising a doubt concerning the truth of the in-
formation described in directions. Moreover, manufacturer 
“A” did not report clinical assays in humans, which may 
suggest that the medicine has no truly proven efficacy or 
safety. 
In the case of information on overdose, manufacturer 
“A” did not report anything about measures that should be 
taken. Manufacturer “B” on the other hand, reported that 
this is a phytotherapeutic medicine which is well tolerated 
and that in case of accidental ingestion of doses which are 
much higher than those recommended, patients must take 
the usual actions to ensure control of vital functions. 
However, manufacturer “B” failed to provide 34.5% 
of the technical information required namely: adjustment 
of the dose for elderly patients and other groups at risk and 
restrictions regarding the use of the medicine, risks of use 
via administration routes that are not recommended, fee-
ding interactions and interactions with laboratory exams, 
necessary procedures in cases of forgetting to administer, 
maximum daily dose, dose for specific illnesses and spe-
cial situations, use in groups at risk and elderly people, 
describing the warnings and the recommendations about 
suitable use. 
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5th Part: Compulsory statements
The required items for compulsory statements, ac-
cording to the legislation, are presented in Table I, which 
shows that manufacturer “A” complied with the legislation 
satisfactorily on 50% of items, but on 25% was considered 
unsatisfactory and failed to present 25% of the items. Ma-
nufacturer “B” satisfactorily conformed to the legislation 
on 91.7% of items while 8.3% of the items were absent 
(Figure 4).
In the part on compulsory statements, manufacturer 
“A” did not include 25% of these, which were: warning to 
pregnant women; statement indicating contra-indication in 
specific age ranges or that there was no contra-indication 
regarding age range; and the statement “Sale under medi-
cal prescription”. The lack of these statements is regarded 
as extremely serious in nature in failing to warn patients 
about the necessary care when using the medicine. 
Concerning the statement “Inform the physician or 
the surgeon-dentist upon the appearance of uncomfortable 
reactions”, Manufacturer “A” did not cite the surgeon-
dentist, although this is understandable given that this 
medicine is not commonly prescribed by dentists. Also, 
the statement “All medications must be kept far from 
children’s reach” was located incorrectly, placed in the 
section addressing health professionals.
Regarding manufacturer “B”, it presented most of 
the compulsory statements (91.67%), however, it failed to 
mention the statement “This medicine is contra-indicated 
in the _____ age range.” or “There are no contra-indica-
tions concerning age range”.
6th Part: Legally required content
Concerning the legal statements, both manufacturers 
presented them all in a satisfactory way, however, manu-
facturer “A” did not cite which Federal unit the technical 
pharmacist responsible for it belonged to (Table I).
The legal content allows verification that the com-
pany is properly regulated, as well as the product it ma-
nufactures. It is important to remember that the inclusion 
of a pharmacist who is technically responsible for the 
manufacture of the medicine is essential.
FIGURE 4 – Evaluation of the item “Compulsory Statements” 
for manufacturer “A” and “B” of P. sidoides  –based 
phytotherapeutics
TABLE I – Standard form for evaluation of package inserts according to RDC 140/2003, employed in the verification of package 
inserts of P. sidoides medicines produced by manufacturers “A” and “B”
SIZE OF LETTERING “A” “B”
Letters a minimum size of 1.5 millimeters S S
IDENTIFICATION OF THE MEDICINE “A” “B”
Commercialized presentations S S
Qualitative and Quantitative description of active compounds A U
Qualitative Description for the other components of the formulation A U
Pharmaceutic Form S S
Commercial name or Brand of the medicine S S
Official botanic nomenclature S S
Part of the plant being used S S
Route of administration S S
Liquid Volume S S
INFORMATION TO PATIENTS “A” “B”
Action of the medicine Action of the medicine after an average time estimated from the onset of 
pharmacological action
U S
Storage of the medicine Specific care for keeping the medicine before and after opening it A U
Indication of the medicine Indications for the use of the medicine S S
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INFORMATION TO PATIENTS “A” “B”
Language Approach Information in accessible language, according to ICD, when referring to 
signs, symptoms and illnesses
U U
Easy-to-understanding text S S
Method of Use
Physical aspect S S
Organoleptic characteristics of the product A A
How to use the medicine S S
Necessary procedure in case of omitting to administrate A S
Duration of the treatment U S
Interval of administration S S
Dosage according to each pharmaceutical form and their respective 
instructions of use
S S
Dosage for specific illnesses and special situations A A
Route of administration S S
Adverse Reactions Most important adverse reactions U U
Warnings S S
Contraindications S S
Precautions S S
Main feeding interactions A A
Risks of the medicine Main interactions with laboratory tests A A
Main medicinal interactions U U
Restrictions for groups at risk A S
Risks of using a route of administration that is not recommended A A
Overdose Procedure in case of overdose, describing the symptoms and measures 
before seeking medical attention
U U
TECHNICAL INFORMATION FOR HEALTH PROFESSIONALS “A” “B”
Warnings Warnings about the medicine A S
Adjustment of dose for elderly patients or groups at risk A A
Categories of risk during pregnancy A S
Recommendations concerning the appropriate use of the medicine A S
Restrictions concerning the use of the medicine A A
Risks of use via a route of administration that is not recommended A A
Storage Care needed for storing U U
Care needed for storing after opening A U
Pharmacological Characteristics Pharmacological characteristics (pharmacodynamics and 
pharmacotechnical)
U U
Contraindication Description of contraindications A S
Indications Indications of the medicine U S
Interactions Feeding interactions A A
Interactions with laboratory exams A A
Medicinal interactions A S
Language Approach According to the recommended terminologies by the ICD 10, when 
referring to symptoms and sicknesses
S S
Way of use Handling and Application A S
Correct method of preparing A S
Correct administration route A S
Necessary procedure in case of omitting to administrate. A A
TABLE I – Standard form for evaluation of package inserts according to RDC 140/2003, employed in the verification of package 
inserts of P. sidoides medicines produced by manufacturers “A” and “B” (cont.)
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TECHNICAL INFORMATION FOR HEALTH PROFESSIONALS “A” “B”
Dosage Dose and duration of the treatment A S
Maximum daily dose A A
Equivalence in weight of the chemical components in the pharmaceutical 
presentation with active substance
U U
Dosage for specific illnesses and special situations A A
Adverse reactions Description of adverse reactions A U
Results of efficacy Results of efficacy based on the percentage of healing or prevention 
in group intervention or group comparison, when available, citing 
bibliographic reference.
A S
Overdose General and specific procedures in event of overdose A U
Use of the medicine in groups 
at risk
Use in children, describing the warnings and recommendations about 
appropriate use
A S
Use in groups at risk, describing the warnings and recommendations 
about appropriate use 
A A
Use in the elderly, describing the warnings and recommendations about 
appropriate use 
A A
COMPULSORY STATEMENTS “A” “B”
Warning addressed to pregnant women A S
“Attention: this is a new medicine, and although studies have shown acceptable efficacy and safety for sale, 
uncomfortable and unknown effects may occur. In the event of problems inform your physician” S S
“Attention: this medicine is a similar that has undergone tests and studies that prove its efficacy, quality and 
safety, according to current legislation”
-- --
“This medicine is contraindicated for the ____ age range” or “There is no contra-indication concerning age 
range”
A A
“Inform your physician or surgeon-dentist upon the appearance of uncomfortable reactions” U S
“Inform your physician or surgeon-dentist if you have been taking any other medicine” U S
“Do not discontinue treatment without consulting your physician” S S
“Do not use any medicines without first notifying your physician. They may be harmful for your health” S S
“Do not use the medicine if the expiry date has elapsed. Before you use the medicine check the condition 
of the medicine”
S S
“Adhere to your physician’s instructions respecting the times, doses and duration of the treatment” S S
“All medicines must be kept out of the reach of children” U S
“Pediatric and /or Adult use” S S
“Sale by doctor’s prescription” A S
LEGALLY REQUIRED CONTENT “A” “B”
Cadastro Nacional de Pessoa Jurídica (CNPJ) S S
Manufacturer’s name S S
Pharmacist in charge with respective registration number and federal unit U S
Manufacturer’s full name S S
Registration number with ANVISA S S
Work telephone number and consumer hotline S S
A = Absent, U = Unsatisfactory, S = Satisfactory
TABLE I – Standard form for evaluation of package inserts according to RDC 140/2003, employed in the verification of package 
inserts of P. sidoides medicines produced by manufacturers “A” and “B” (cont.)
CONCLUSIONS
Analysis of “A” and “B” manufacturers’ package 
inserts revealed that neither fully conformed to the cur-
rent legislation, either omitting or presenting information 
necessary for both patients and health professionals, in 
an unsatisfactory manner, even almost five years after 
normative publication (RDC 140/03).
Concerning manufacturer “A”, it met the require-
ments of the legislation satisfactorily on only 37.04% of 
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items, whereas 16.05% of the information was regarded 
as unsatisfactory and 46.91% of items were absent. The 
technical information was of extremely poor quality, 
describing only 3.45% of the items satisfactorily, 10.34% 
unsatisfactorily while omitting 86.21% of the legally re-
quired information.
 Moreover, manufacturer “B” conformed to the 
legislatory requirements satisfactorily on 64.20% of 
items, whereas 16.05% were considered unsatisfactory 
and 19.75% absent. This manufacturer attempted to meet 
requirements in a simple and clear fashion, besides fully 
outlining the sources used for its production and provided 
evidence for these claims.
According to the Consumer Defense Code, all ci-
tizens have the fundamental right to access appropriate 
and clear information about products and services (Brasil, 
1990). However, this right was not fully respected by ei-
ther manufacturer, particularly in the case of manufacturer 
“A”.
The directions provided by manufacturer “A” do 
provide sufficient instructions for patients or health pro-
fessionals.
A medicine package insert is expected to present 
quality information for both user and health professional. 
However, the results obtained in this study indicated that 
the information presented in the package inserts for both 
medicines were incomplete and in many cases breached 
the current legislation.
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